Actinium Pharmaceuticals/$ATNM
1D1W1MYTD1Y5YMAX
About Actinium Pharmaceuticals
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
- Ticker
- $ATNM
- Sector
- Health
- Primary listing
- AMEX
- Employees
- 27
- Headquarters
- New York, United States
- Website
- www.actiniumpharma.com
ATNM Metrics
BasicAdvanced
$32M
2.84
$0.36
0.02
-
Price and volume
Market cap
$32M
Beta
0.02
52-week high
$1.80
52-week low
$0.74
Average daily volume
153K
Financial strength
Current ratio
4.076
Quick ratio
3.939
Long term debt to equity
1.964
Total debt to equity
4.425
Profitability
EBITDA (TTM)
9.791
Gross margin (TTM)
100.00%
Net profit margin (TTM)
32.23%
Operating margin (TTM)
27.23%
Revenue per employee (TTM)
$1,300,000
Management effectiveness
Return on assets (TTM)
11.58%
Return on equity (TTM)
45.86%
Valuation
Price to earnings (TTM)
2.838
Price to revenue (TTM)
0.9
Price to book
1.05
Price to tangible book (TTM)
1.05
Price to free cash flow (TTM)
-1.358
Free cash flow yield (TTM)
-73.64%
Free cash flow per share (TTM)
-0.744
Growth
Earnings per share change (TTM)
-127.03%
3-year revenue growth (CAGR)
820.43%
3-year earnings per share growth (CAGR)
-41.81%
10-year earnings per share growth (CAGR)
-31.17%
What the Analysts think about ATNM
Analyst ratings (Buy, Hold, Sell) for Actinium Pharmaceuticals stock.
ATNM Financial Performance
Revenues and expenses
ATNM Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.